CA2558212C - Interferon-beta for anti-virus therapy for respiratory diseases - Google Patents

Interferon-beta for anti-virus therapy for respiratory diseases Download PDF

Info

Publication number
CA2558212C
CA2558212C CA2558212A CA2558212A CA2558212C CA 2558212 C CA2558212 C CA 2558212C CA 2558212 A CA2558212 A CA 2558212A CA 2558212 A CA2558212 A CA 2558212A CA 2558212 C CA2558212 C CA 2558212C
Authority
CA
Canada
Prior art keywords
ifn
cells
infection
agent
asthmatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2558212A
Other languages
English (en)
French (fr)
Other versions
CA2558212A1 (en
Inventor
Donna Elizabeth Davies
Peter Alexander Blanch Wark
Stephen Holgate
Sebastian L. Johnston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southampton
Original Assignee
University of Southampton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southampton filed Critical University of Southampton
Priority to CA2787978A priority Critical patent/CA2787978A1/en
Publication of CA2558212A1 publication Critical patent/CA2558212A1/en
Application granted granted Critical
Publication of CA2558212C publication Critical patent/CA2558212C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CA2558212A 2004-03-12 2005-03-07 Interferon-beta for anti-virus therapy for respiratory diseases Expired - Lifetime CA2558212C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2787978A CA2787978A1 (en) 2004-03-12 2005-03-07 Interferon-beta for anti-virus therapy for respiratory diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0405634.7 2004-03-12
GBGB0405634.7A GB0405634D0 (en) 2004-03-12 2004-03-12 Anti-virus therapy for respiratory diseases
PCT/GB2005/050031 WO2005087253A2 (en) 2004-03-12 2005-03-07 Interferon-beta for anti-virus therapy for respiratory diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2787978A Division CA2787978A1 (en) 2004-03-12 2005-03-07 Interferon-beta for anti-virus therapy for respiratory diseases

Publications (2)

Publication Number Publication Date
CA2558212A1 CA2558212A1 (en) 2005-09-22
CA2558212C true CA2558212C (en) 2012-11-27

Family

ID=32117582

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2558212A Expired - Lifetime CA2558212C (en) 2004-03-12 2005-03-07 Interferon-beta for anti-virus therapy for respiratory diseases
CA2787978A Abandoned CA2787978A1 (en) 2004-03-12 2005-03-07 Interferon-beta for anti-virus therapy for respiratory diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2787978A Abandoned CA2787978A1 (en) 2004-03-12 2005-03-07 Interferon-beta for anti-virus therapy for respiratory diseases

Country Status (12)

Country Link
US (3) US7569216B2 (enExample)
EP (2) EP1734987B1 (enExample)
JP (2) JP4807526B2 (enExample)
AT (1) ATE466591T1 (enExample)
CA (2) CA2558212C (enExample)
DE (1) DE602005021078D1 (enExample)
DK (1) DK1734987T3 (enExample)
ES (1) ES2343732T3 (enExample)
GB (1) GB0405634D0 (enExample)
PL (1) PL1734987T3 (enExample)
PT (1) PT1734987E (enExample)
WO (1) WO2005087253A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
US8318423B2 (en) * 2004-07-06 2012-11-27 Focus Diagnostics, Inc. Methods and compositions for detecting rhinoviruses
JP5172679B2 (ja) * 2005-09-09 2013-03-27 インペリアル イノベーションズ リミテッド 呼吸器疾患の治療のためのインターフェロン−λ療法
CN101378774A (zh) * 2005-09-20 2009-03-04 纽约大学 用干扰素治疗肺病的方法
DE102006022877B4 (de) 2006-05-15 2009-01-29 Sartorius Stedim Biotech Gmbh Verfahren zur Bestimmung der Viabilität von Zellen in Zellkulturen
US7871603B2 (en) 2007-05-18 2011-01-18 Synairgen Research Limited Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly
GB0713402D0 (en) * 2007-07-11 2007-08-22 Cardiff & Vale Nhs Trust A method of diagnosing a condition using a neural network
TW200938222A (en) * 2007-12-13 2009-09-16 Glaxo Group Ltd Compositions for pulmonary delivery
EP2373329A4 (en) * 2008-12-19 2012-07-04 Univ California USE OF INGREDIENTS OF THE EPIDERMAL GROWTH FACTOR IN THE TREATMENT OF VIRUS INFECTIONS
EP2506759A4 (en) * 2009-12-02 2015-05-20 Neetour Medical Ltd SURVEILLANCE BASED ON HEMODYNAMIA AND ASSESSMENT OF RESPIRATORY DISEASES
SI2544705T1 (sl) * 2010-03-12 2016-11-30 Synairgen Research Limited Interferon beta za uporabo pri zdravljenju bolezni spodnjega dihalnega trakta, povzročene z influenco
WO2012037612A1 (en) 2010-09-22 2012-03-29 The University Of Melbourne Novel immunostimulatory method
CN109293782A (zh) 2014-01-08 2019-02-01 德益阳光生物技术（北京）有限责任公司 融合多肽及使用方法
US12083228B2 (en) 2017-07-24 2024-09-10 Novavax, Inc. Methods and compositions for treating respiratory disease
PL3728289T3 (pl) 2017-12-21 2026-01-26 Axelia Oncology Pty Ltd Zoptymalizowane związki
US20220233643A1 (en) * 2019-02-13 2022-07-28 University Of Florida Research Foundation, Incorporated TARGETING LUNG-RESIDENT TNFR2+ cDC2 (R2D2) SUBPOPULATION TO TREAT ASTHMA
JP2022539091A (ja) 2019-06-26 2022-09-07 アクセリア オンコロジー ピーティーワイ リミテッド 新規な分子
US20230338475A1 (en) 2020-07-20 2023-10-26 Synairgen Research Limited USE OF INHALED INTERFERON-BETA TO IMPROVE OUTCOME IN SARS-CoV-2 INFECTED PATIENTS
GB202014114D0 (en) * 2020-09-08 2020-10-21 Synairgen Res Ltd Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid
WO2022096582A1 (en) * 2020-11-04 2022-05-12 Ethris Gmbh Use of ifn-lambda mrna for treating viral infections
US20250281576A1 (en) * 2021-01-13 2025-09-11 Abion Inc. Prophylactic administration method against respiratory virus, comprising administering interferon-beta to potential respiratory virus-infected subject

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596260B1 (en) * 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
NZ285664A (en) * 1994-05-18 1998-07-28 Inhale Therapeutic Syst Dry powder interferon composition adapted for pulmonary delivery
US6030609A (en) 1995-05-19 2000-02-29 Case Western Reserve University Method and composition for treating paramyxovirus
US20010031253A1 (en) * 1996-07-24 2001-10-18 Gruenberg Micheal L. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
AU780270B2 (en) * 2000-02-23 2005-03-10 Association Francaise Contre Les Myopathies Treatment of immune diseases
GB2362884A (en) 2000-05-30 2001-12-05 Isis Innovation Extended duration of airway gene therapy
WO2002036628A2 (en) 2000-11-02 2002-05-10 Maxygen Aps New multimeric interferon beta polypeptides
WO2002072019A2 (en) * 2001-03-13 2002-09-19 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
WO2003066002A2 (en) 2002-02-08 2003-08-14 University Of Medicine And Dentistry Of New Jersey IFN-a/b-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
JP2006509041A (ja) 2002-10-23 2006-03-16 ザイモジェネティクス，インコーポレイティド Ｉｌ−２８およびｉｌ−２９を用いるウイルス感染を治療するための方法
PT2251353E (pt) 2003-08-07 2013-05-07 Zymogenetics Inc Preparações homogéneas de il-28 e il-29
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
JP4896005B2 (ja) 2004-04-02 2012-03-14 ザイモジェネティクス リミテッド ライアビリティ カンパニー Ｉｌ−２８およびｉｌ−２９システイン変異体を用いるウイルス感染を治療するための方法

Also Published As

Publication number Publication date
DE602005021078D1 (de) 2010-06-17
EP1734987B1 (en) 2010-05-05
EP1734987A2 (en) 2006-12-27
US20070134763A1 (en) 2007-06-14
JP4807526B2 (ja) 2011-11-02
CA2558212A1 (en) 2005-09-22
GB0405634D0 (en) 2004-04-21
WO2005087253A3 (en) 2005-11-24
WO2005087253A2 (en) 2005-09-22
ATE466591T1 (de) 2010-05-15
EP2206512A2 (en) 2010-07-14
US8273342B2 (en) 2012-09-25
ES2343732T3 (es) 2010-08-09
JP2007528890A (ja) 2007-10-18
CA2787978A1 (en) 2005-09-22
DK1734987T3 (da) 2010-08-30
JP2011144201A (ja) 2011-07-28
EP2206512A3 (en) 2013-01-09
HK1097181A1 (en) 2007-06-22
PT1734987E (pt) 2010-07-06
US20090257980A1 (en) 2009-10-15
PL1734987T3 (pl) 2010-10-29
US7569216B2 (en) 2009-08-04
US20130209399A1 (en) 2013-08-15
US9089535B2 (en) 2015-07-28

Similar Documents

Publication Publication Date Title
EP1734987B1 (en) Interferon-beta for anti-virus therapy for respiratory diseases
Schloer et al. The annexin A1/FPR2 signaling axis expands alveolar macrophages, limits viral replication, and attenuates pathogenesis in the murine influenza A virus infection model
Clementi et al. Viral respiratory pathogens and lung injury
Gwyer Findlay et al. Cationic host defence peptides: potential as antiviral therapeutics
Herold et al. Influenza virus-induced lung injury: pathogenesis and implications for treatment
KR20220147121A (ko) 가용성 ace2 및 융합 단백질, 및 이의 응용
Cipolla et al. Influenza sequelae: from immune modulation to persistent alveolitis
Peng et al. Mechanisms and treatments of myocardial injury in patients with corona virus disease 2019
He et al. C-fiber degeneration enhances alveolar macrophage-mediated IFN-α/β response to respiratory syncytial virus
Abdul-Hafez et al. Angiotensin Converting Enzyme-2 (ACE-2) role in disease and future in research
US20220008507A1 (en) Methods and compositions for treatment of coronavirus infection and associated coagulopathy
EP2544705B1 (en) Interferon beta for use in the treatment of lower respiratory tract illness caused by influenza
WO2025088160A1 (en) Transmembrane serine protease and neutrophil elastase inhibitors
HK1145985A (en) Increase of interferon-beta for anti-virus therapy for respiratory diseases
HK1146217A (en) Increase of interferon-beta for anti-virus therapy for respiratory diseases
HK1097181B (en) Interferon-beta for anti-virus therapy for respiratory diseases
Sousa et al. Antiviral host defence peptides
Tavakol et al. The world against versatile SARS-Cov-2 nanomachines: mythological or reality?
US7871603B2 (en) Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly
CA2632032C (en) Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly
WO2008134123A1 (en) Ul97 for treatment of protein aggregate disorders
Kolli et al. Alveolar Macrophages Contribute to the Pathogenesis of hMPV Infection While Protecting 1 Against RSV Infection 2
Hsu et al. Innate immunity in the airways to respiratory viruses

Legal Events

Date Code Title Description
EEER Examination request
H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20240909